Moleculin Biotech Announces Imminent Unblinding of Pivotal MIRACLE Trial Data for Annamycin in R/R AML
Houston, TX — May 13, 2026 — Moleculin Biotech, Inc. (NASDAQ: MBRX), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, has issued a significant update regarding its leading clinical program. The company has announced that it is rapidly approaching the first unblinding of data from its pivotal Phase 2B/3 “MIRACLE” trial, which is evaluating its proprietary drug Annamycin in combination with cytarabine for the treatment of subjects with relapsed or refractory acute myeloid leukemia (R/R AML).
Key Highlights for Investors
- Imminent Data Unblinding: Moleculin expects the unblinding of the first tranche of data from the MIRACLE trial to occur before June 30, 2026, as previously communicated. This milestone is considered pivotal for the future of Annamycin and could be price sensitive given its potential to impact regulatory and commercial prospects.
- Trial Design and Scope: The MIRACLE trial is a pivotal Phase 2B/3 study comparing two different dosing arms of Annamycin plus cytarabine against a control arm of cytarabine plus placebo in patients with R/R AML who have failed their primary line of therapy. The trial’s design is intended to robustly evaluate efficacy and safety, with the aim of supporting potential regulatory submission.
- Blinded Data Outperformance: The company stated that blinded data from the ongoing trial “continue to significantly outperform historical benchmarks.” While specific efficacy data remain undisclosed until unblinding, this statement suggests strong potential clinical activity, which could be highly material for future share value.
- Potential Regulatory Implications: If the unblinded data confirm the positive trends suggested by blinded results, this could substantially de-risk the MIRACLE program, accelerate regulatory submission for Annamycin, and potentially position Moleculin Biotech as a leader in the R/R AML treatment landscape.
- Safety Profile: Moleculin highlighted Annamycin’s favorable safety and tolerability profile, specifically emphasizing the absence of cardiotoxicity—a significant differentiator from traditional anthracycline chemotherapies, which are commonly associated with heart-related side effects.
- Financing Requirements: The company disclosed that it will require significant additional financing to complete its clinical trials as described, and currently has no commitments for such funding. The achievement of the milestones described, including continued trial progress, is contingent on Moleculin’s ability to secure timely financing. This is an important risk factor for shareholders to monitor, as delays or difficulties in funding could impact the pace of development and, consequently, the share price.
What Should Shareholders Watch?
- Pivotal Data Release Timeline: The market will be closely watching for the MIRACLE trial’s unblinded data before the end of the second quarter of 2026. Positive results could lead to a significant re-rating of the company’s valuation, while disappointing data could have the opposite effect.
- Regulatory and Commercial Pathways: The quality of the upcoming data will inform the likelihood of regulatory approval and commercialization prospects for Annamycin in R/R AML.
- Financing Announcements: With no committed financing for ongoing and future trials, any capital raise, partnership, or other funding event could materially impact the company’s financial health and share price.
- Safety Signals: Continued demonstration of a lack of cardiotoxicity could make Annamycin an attractive alternative to existing therapies, further boosting its market potential.
Other Important Information
The company has attached its press release as Exhibit 99.1 to the SEC Form 8-K filing. Moleculin also notes that the information provided in the filing, including the press release, is furnished and not filed for the purposes of the Securities Exchange Act of 1934 or the Securities Act of 1933, which means it may not be subject to certain legal liabilities associated with “filed” information.
Forward-looking statements in the company’s disclosure include expectations about the timing of data unblinding, regulatory prospects, safety profile, and the need for additional financing. Shareholders should be aware that actual results could differ materially due to various risks, including clinical trial outcomes, regulatory decisions, competitive pressures, and the ability to secure financing.
Contact Information for Investors
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
Disclaimer:
This article is based on Moleculin Biotech, Inc.’s public SEC filings and press releases as of May 13, 2026. It contains forward-looking statements that involve risks and uncertainties. Investors should exercise caution and perform their own due diligence before making any investment decisions. This article does not constitute investment advice. Moleculin Biotech’s actual results may differ materially from those anticipated in forward-looking statements due to a variety of factors, including those discussed under “Risk Factors” in the company’s most recent SEC filings.
